AGIOS PHARMACEUTICALS, INC. Quarterly Debt-to-equity in % from Q1 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Agios Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2018 to Q3 2024.
  • Agios Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 13.3 %, a 7.11% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 13.3 +0.88 +7.11% Sep 30, 2024
Q2 2024 15 +2.85 +23.5% Jun 30, 2024
Q1 2024 13.9 +2.04 +17.2% Mar 31, 2024
Q4 2023 13 +1.33 +11.4% Dec 31, 2023
Q3 2023 12.4 +0.99 +8.69% Sep 30, 2023
Q2 2023 12.1 +1.19 +10.9% Jun 30, 2023
Q1 2023 11.9 +1.64 +16.1% Mar 31, 2023
Q4 2022 11.7 +2.21 +23.3% Dec 31, 2022
Q3 2022 11.4 -4.86 -29.9% Sep 30, 2022
Q2 2022 11 -14.1 -56.3% Jun 30, 2022
Q1 2022 10.2 -29.7 -74.4% Mar 31, 2022
Q4 2021 9.5 -61.9 -86.7% Dec 31, 2021
Q3 2021 16.3 -38.9 -70.5% Sep 30, 2021
Q2 2021 25 -23.1 -47.9% Jun 30, 2021
Q1 2021 39.9 -1.3 -3.15% Mar 31, 2021
Q4 2020 71.4 +28.9 +67.9% Dec 31, 2020
Q3 2020 55.1 +16.9 +44.3% Sep 30, 2020
Q2 2020 48.1 +17.6 +57.7% Jun 30, 2020
Q1 2020 41.2 +16.4 +66.3% Mar 31, 2020
Q4 2019 42.5 +20.6 +93.5% Dec 31, 2019
Q3 2019 38.2 +11.4 +42.4% Sep 30, 2019
Q2 2019 30.5 -2.37 -7.21% Jun 30, 2019
Q1 2019 24.8 -16.2 -39.6% Mar 31, 2019
Q4 2018 22 Dec 31, 2018
Q3 2018 26.8 Sep 30, 2018
Q2 2018 32.9 Jun 30, 2018
Q1 2018 41 Mar 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.